AbbVie Inc. (NYSE: ABBV ) released Q2 2025 earnings confirming the extraordinary performance of Skyrizi and Rinvoq, which accounted for $6.4 billion in global sales, 41% of AbbVie’s total revenues for Q2. More importantly, both products are demonstrating theirOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have been utilising my background in l ...

Core Insights - The article discusses Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) and its reliance on the drug Zoryve, which raises skepticism about the company's ability to generate shareholder returns [1]. Company Analysis - Arcutis Biotherapeutics has been previously rated as a Hold due to its dependence on Zoryve [1]. - The company is involved in the research and development of novel Cell & Gene Therapies (CGT) aimed at addressing various clinical needs [1]. Analyst Background - The analyst has over 20 years of experience in life sciences, focusing on biotechnology, pharmaceuticals, Medtech, and healthcare stocks [1]. - The analyst utilizes a strong background in biomedicine and bioengineering to evaluate the potential of new treatments and their impact on shareholder returns [1].